Adc Therapeutics SA (ADCT) saw an uptrend of 766422% in the recent trading with $588550.0 being its most recent. The current price level -30.99% lower than the highest price of $4.13 marked by the stock while trading over the past 52-weeks, whereas it is 171.43% higher than the lowest price of $1.05 the company dropped to over past 52-weeks. The latest news story on ADCT appeared in (PR Newswire) under the title “ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)” on Jun-16-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 7 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Adc Therapeutics SA Earnings – What Happened With ADCT
Coming around sales and income figures on ADCT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Adc Therapeutics SA – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 99.18 million. ADCT does have institutional investors; and they hold 61.51% of the stock.
As on 2024-06-30, REDMILE GROUP, LLC was the top most holder in Adc Therapeutics SA (NYSE:ADCT) with an ownership of 15.27 million shares of the company or 15.9568 of the stake worth $48.25 million. The filing also reveals PROSIGHT MANAGEMENT, LP as the second largest holder in the company with a control over 10.0009 of the outstanding shares. Its stake is worth $30.24 million for having 9.57 million shares in hand.
ORBIMED ADVISORS LLC also came holding a key position in the company during the recent quarter and it now holds 4.5112 of the outstanding shares. With this there are now 115.0 institutions which have possession in ADCT’s shares.
Key Metrics forADCT
Technical Analysis of Adc Therapeutics SA (NYSE:ADCT) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Adc Therapeutics SA (ADCT), we notice that the stock’s 20-day average volume is at 912,475 shares and 50% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 641,554 shares. And to end, ADCT’s 100-day average volume is 524,741 shares with 50% of the long-term indicators pointing towards Buy for the stock.
